IDEAYA Biosciences, Inc. (IDYA): Operating Income
-$159.31M
Year ended 2025-12-31
-$216.95M
Trailing 12 months to 2026-06-30
| Period ended | Operating Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$159.31M | n/m | 2026-02-17, From 2025-01-01 |
| 2024-12-31 | -$326.98M | n/m | 2026-02-17, From 2024-01-01 |
| 2023-12-31 | -$134.43M | n/m | 2026-02-17, From 2023-01-01 |
| 2022-12-31 | -$62.50M | n/m | 2025-02-18, From 2022-01-01 |
| 2021-12-31 | -$50.27M | n/m | 2024-02-20, From 2021-01-01 |
| 2020-12-31 | -$35.34M | n/m | 2023-03-07, From 2020-01-01 |
| 2019-12-31 | -$44.27M | n/m | 2022-03-18, From 2019-01-01 |
| 2018-12-31 | -$36.42M | n/m | 2021-03-23, From 2018-01-01 |
| 2017-12-31 | -$14.44M | n/a | 2020-03-24, From 2017-01-01 |
Operating Income at similar companies
| Company | Year ended | Operating Income | Change YoY |
|---|---|---|---|
| IDEAYA Biosciences, Inc. (IDYA) | 2025-12-31 | -$159.31M | n/m |
| Vanda Pharmaceuticals Inc. (VNDA) | 2025-12-31 | -$151.17M | n/m |
| Amarin Corp PLC (AMRN) | 2025-12-31 | -$50.17M | n/m |
| Puma Biotechnology, Inc. (PBYI) | 2025-12-31 | $37.30M | +20.5% |
| Anaptysbio, Inc (ANAB) | 2025-12-31 | $47.90M | n/m |
| Akebia Therapeutics, Inc. (AKBA) | 2025-12-31 | $23.50M | n/m |
| Keros Therapeutics, Inc. (KROS) | 2025-12-31 | $67.57M | n/m |
| Arcus Biosciences, Inc. (RCUS) | 2025-12-31 | -$386.00M | n/m |
| Rhythm Pharmaceuticals, Inc. (RYTM) | 2025-12-31 | -$192.02M | n/m |
Compare IDYA, VNDA, AMRN, PBYI side by side · Screen every company in Pharmaceutical Preparations ↗